Clinical trial

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

NCT07287995

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-02-05

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2026-02-05Date precision: day

Registry last updated2026-09-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Locally Advanced or Metastatic Malignant Solid Tumorsunresolved

Interventions

ASP2998DRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Enfortumab VedotinDRUG · verified · RxNorm: enfortumab vedotin

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Astellas Pharma Global Development, Inc.lead sponsor

Mapped research locations

NashvilleTennessee, United States1 FairfaxVirginia, United States1 HackensackNew Jersey, United States1 New Hyde ParkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07287995 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.